


PERSONAL INFORMATION

Vittorio Maglione


 Twitter

Sex | Date of birth | Nationality

ESPERIENZA
PROFESSIONALE

Giugno 2015 – in corso

Responsabile Laboratorio di Neurogenetica e Malattie Rare
IRCCS Neuromed, Pozzilli (IS)

Giugno 2013 – Giugno 2015

Marie Curie Research Associate
IRCCS Neuromed, Pozzilli (IS)

Gennaio 2012 – Giugno 2013

Post-Doc Senior
IRCCS Neuromed, Pozzilli (IS)

Gennaio 2011 – Dicembre 2011

Research Associate
University of Alberta, Edmonton, Canada

Gennaio 2008 – Dicembre 2010

AHFMR Post-Doctoral Fellow,
University of Alberta, Edmonton, Canada

Gennaio 2005 – Dicembre 2007

Post-Doc
IRCCS Neuromed, Pozzilli (IS)

Gennaio 2001 – Dicembre 2004

Studente di Dottorato
IRCCS Neuromed/Università di Catania

Gennaio 1999 – Dicembre 2000

Borsa di studio per Ricerca
IRCCS Neuromed, Pozzilli (IS)

ISTRUZIONE E FORMAZIONE

Gennaio 2005

PhD in Neurobiology
IRCCS Neuromed/Università di Catania

1999

Abilitazione alla professione di Biologo

Luglio 1998

Laurea in Scienze Biologiche (110/110 cum laude)
Facoltà di Scienze Biologiche, Università di Napoli "Federico II"

Competenze personali

Mother tongue(s) Italian

Other language(s)

English

| UNDERSTANDING | | SPEAKING | | WRITING |
|---------------|---------|--------------------|-------------------|---------|
| Listening | Reading | Spoken interaction | Spoken production | |
| C2 | C2 | C2 | C2 | C2 |

ADDITIONAL INFORMATION

Abilitazioni (ASN)

2023–2034- Italian National Scientific Qualification as **Associate Professor** in Medical Genetics (**MED/03**)
2023–2034- Italian National Scientific Qualification as **Associate Professor** in General Pathology (**MED/04**)
2023–2034- Italian National Scientific Qualification as **Associate Professor** in 06/N1 - Technology and methodology in medicine and nursing sciences (**MED/46**)
2023–2034- Italian National Scientific Qualification as **Full Professor** in Biochemistry (**BIO/10**)
2020–2031- Italian National Scientific Qualification as **Associate Professor** in Biochemistry (**BIO/10**)
2017- 2028- Italian National Scientific Qualification as **Associate Professor** in Applied Biology (**BIO/13**).

Attività didattica

2019 - 2023- Instructor of “*Applied Biology*” (**BIO/13**) for 1st year students, Bachelor degree in “Speech Therapy”. Neuromed Institute and University of Rome “Tor Vergata”.
2019 – 2023- Instructor of “*Biochemistry*” (**BIO/10**) for 1st year students, Bachelor degree in “Speech Therapy”. Neuromed Institute and University of Rome “Tor Vergata”.
2001-2007- Instructor – Integrated Course of “Clinical Biochemistry and Clinical Molecular Biology”, discipline: “*Molecular Diagnostic*” for 3rd year students, Bachelor degree in Science and Biomedical Technologies. Neuromed Institute and “Sapienza” University of Rome.

Finanziamenti in corso

2022-2024- Cariplo-Telethon Grant GJC21 57A. [Discovery of novel genes involved in Huntington's Disease pathogenesis](#). **Co-Investigator**
2021-2024- Telethon Grant GGP20101. Metabolism of polysialic acid: new insight into pathological mechanisms and potential treatments for Huntington's disease. **Principal Investigator**.
2022-2024- “Ricerca Corrente” Grant Program (Italian Ministry of Health). Investigation of sphingolipid metabolism in neurological disorders including Rare Diseases: discovery of new potential therapeutic targets. **Principal Investigator**.
2022-2024- “Ricerca Corrente” Grant Program (Italian Ministry of Health). Analysis of pathogenic mechanisms and identification of new potential therapeutic targets for brain disorders including Rare Diseases. **Principal Investigator**.

Attività editoriale

- **Handing Editor**, *Journal of Neurochemistry*
- **Associate Editor**, *Behavioural Brain Research* (2023-2025)

Affiliazione a Società Scientifiche

- **Membro** *Huntington Study Group (HSG)*
- **Membro** *European Huntington Disease Network (EHDN)*
- **Referente Scientifico** of the *Sphingolipid Club*

Premi e riconoscimenti

2012 – “Marie Curie” International Incoming Fellowship Award (**Role of sphingolipids in white matter dysfunction in Huntington's disease**. PIIF-GA-2011-300197.
2011 – University of Alberta, Department of Pharmacology Annual Retreat – Best Poster Presentation Award, for Postdoctoral research.
2010 – University of Alberta – Med Star Postdoctoral Award. *This award recognizes the best research*

contributions of Postdoctoral fellows at the University of Alberta, Edmonton-Canada

2010 – University of Alberta Translational Neuroscience Symposium – Poster Prize for the best post-doctoral research.

2010 – University of Alberta, Department of Pharmacology Annual Retreat – Honorable Mention for Postdoctoral research.

2009 – University of Alberta, Department of Pharmacology Annual Retreat – Honorable Mention for Postdoctoral research.

2008-2010 – Alberta Heritage For Medical Research (AHFMR) Postdoctoral Fellowship Award.

2005-2007 – Postdoctoral fellowship, Neuromed Institute, Pozzilli, Italy

2001-2004 – PhD studentship, University of Catania, Catania, Italy

1999-2001 – Italian Ministry of University and Scientific Research (MURST) Award

Brevetti

Patent number: US 9023812 B2. Country: USA. Status: approvato

Titolo del brevetto: **Neuroprotective ganglioside compositions for use in treating Huntington's disease**

Co-inventori: Simonetta Sipione, **Vittorio Maglione**

Description and relevance of the invention: Development of a novel therapy for Huntington's disease.

Organizzazione Congressi

Chair of the **14th Sphingolipid Club (SLC) International Meeting**

(<https://www.sphingolipidclub.com/meetings/14th-meeting/>) - September 7-11, 2022. Pozzilli (IS), Italy

Chair of the **"ISN Symposium: Sphingolipids and brain: pathophysiology and therapeutics"** - 14th SLC International Meeting – September 1 , 2022, Pozzilli (IS), Italy

Partecipazione su invito ai Congressi

Italian Mass Spectrometry Society. IMaSS Lipidomics Day 2021- September 14, 2021. Online event.

Title of contribution: **"Sphingolipid derangement in Huntington's disease"**

FEBS 2019 Advance Course - Sphingolipid Biology: Sphingolipids in Physiology and Pathology - May 26-10, 2019 Cascais, Portugal

Title of contribution: **"Sphingolipid metabolism: new perspectives for treating Huntington's disease"**.

4th Glycobiology World Congress. September 17-19, 2018. Rome, Italy

Title of contribution: **"Glycoconjugate metabolism: A common player for different brain disorders"**.

2nd International Conference on Neurology and Brain Disorders (INBC). June 4-6, 2018. Rome, Italy

Title of contribution: **"New perspectives for a more suitable therapeutic approach for Huntington's disease"**.

Sphingolipid Club Meeting 2018- ISN symposium – SLs and Disorders of the Nervous System. September 6-10, 2017. Trabia, Italy

Title of the contribution: **"SLs: new insight for a more suitable therapeutic approach for Huntington's Disease"**.

Gordon Research Conference. Glycolipid and Sphingolipid Biology. March 6-11, 2016. Renaissance Il Ciocco, Lucca (Barga) - Italy.

Title of the contribution: **"Sphingolipid Metabolism in Huntington's Disease: New Perspectives into Pathogenesis and Potential Treatment"**.

Pubblicazioni scientifiche

1. Servettini I, Talani G, Megaro A, Setzu MD, Biggio F, Briffa M, Guglielmi L, Savalli N, Binda F, Delicata F, Bru-Mercier G, Vassallo N, **Maglione V**, Cauchi RJ, Di Pardo A, Collu M, Imbrici P, Catacuzzeno L, D'Adamo MC, Olcese R, Pessia M. An activator of voltage-gated K⁺ channels Kv1.1 as a therapeutic candidate for episodic ataxia type 1. *Proc Natl Acad Sci U S A*. 2023 Aug;120(31):e2207978120. doi: 10.1073/pnas.2207978120.
 2. Ferlazzo GM, Gambetta AM, Amato S, Cannizzaro N, Angiolillo S, Arboit M, Diamante L, Carbognin E, Romani P, La Torre F, Galimberti E, Pflug F, Luoni M, Giannelli S, Pepe G, Capocci L, Di Pardo A, Vanzani P, Zennaro L, Broccoli V, Leeb M, Moro E, **Maglione V**, Martello G. Genome-wide screening in pluripotent cells identifies Mtf1 as a suppressor of mutant huntingtin toxicity. *Nat Commun*. 2023 Jul 5;14(1):3962. doi: 10.1038/s41467-023-39552-9.
 3. Pepe, G.; Fioriniello, S.; Marracino, F.; Capocci, L.; **Maglione, V.**; D'Esposito, M.; Di Pardo, A.; Della Ragione, F. Blood–Brain Barrier Integrity Is Perturbed in a *Mecp2*-Null Mouse Model of Rett Syndrome. *Biomolecules* **2023**, *13*, 606. <https://doi.org/10.3390/biom13040606>
 4. Pepe G, Lenzi P, Capocci L, Marracino F, Pizzati L, Scarselli P, Di Pardo A, Fornai F, **Maglione V**. Treatment with the Glycosphingolipid Modulator THI Rescues Myelin Integrity in the Striatum of R6/2 HD Mice. *Int J Mol Sci*. 2023 Mar 22;24(6):5956. doi: 10.3390/ijms24065956.
 5. Palomba NP, Fortunato G, Pepe G, Modugno N, Pietracupa S, Damiano I, Mascio G, Carrillo F, Di Giovannantonio LG, Ianiro L, Martinello K, Volpato V, Desiato V, Aciri R, Storto M, Nicoletti F, Webber C, Simeone A, Fucile S, **Maglione V**, Esposito T. Common and Rare Variants in TMEM175 Gene Concur to the Pathogenesis of Parkinson's Disease in Italian Patients. *Mol Neurobiol*. 2023 Apr;60(4):2150-2173. doi: 10.1007/s12035-022-03203-9
 6. Burtscher J*, Pepe G, Maharjan N, Riguet N, Di Pardo A, **Maglione V***, Millet GP. Sphingolipids and impaired hypoxic stress responses in Huntington disease. *Prog Lipid Res*. 2023 Mar 8;90:101224. doi: 10.1016/j.plipres.2023.101224.
- *Co-Corresponding Authors**
7. Pepe G, Capocci L, Marracino F, Realini N, Lenzi P, Martinello K, Bovier TF, Bichell TJ, Scarselli P, Di Cicco C, Bowman AB, Digilio FA, Fucile S, Fornai F, Armirotti A, Parlato R, Di Pardo A, **Maglione V**. Treatment with THI, an inhibitor of sphingosine-1-phosphate lyase, modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington's disease. *Mol Ther*. 2022 Sep 16:S1525-0016(22)00558-5.
 8. Rosa P, Scibetta S, Pepe G, Mangino G, Capocci L, Moons SJ, Boltje TJ, Fazi F, Petrozza V, Di Pardo A, **Maglione V**, Calogero A. Polysialic Acid Sustains the Hypoxia-Induced Migration and Undifferentiated State of Human Glioblastoma Cells. *Int J Mol Sci*. 2022 Aug 24;23(17):9563.
 9. Burtscher J, Pepe G, Marracino F, Capocci L, Giova S, Millet GP, Di Pardo A, **Maglione V**. Brain Region and Cell Compartment Dependent Regulation of Electron Transport System Components in Huntington's Disease Model Mice. *Brain Sci*. 2021 Sep 24;11(10):1267.
 10. Forte M, Bianchi F, Cotugno M, Marchitti S, Stanzione R, **Maglione V**, Sciarretta S, Valenti V, Carnevale R, Versaci F, Frati G, Volpe M, Rubattu S. An interplay between UCP2 and ROS protects cells from high-salt-induced injury through autophagy stimulation. *Cell Death Dis*. 2021 Oct 8;12(10):919.
 11. Mingione A, Pivari F, Plotegher N, Dei Cas M, Zulueta A, Bocci T, Trinchera M, Albi E, **Maglione V**, Caretti A, Bubacco L, Paroni R, Bottai D, Ghidoni R, Signorelli P. Inhibition of Ceramide Synthesis Reduces α -Synuclein Proteinopathy in a Cellular Model of Parkinson's Disease. *Int J Mol Sci*. 2021 Jun 16;22(12):6469.

12. Pepe G, Cotugno M, Marracino F, Giova S, Capocci L, Forte M, Stanzione R, Bianchi F, Marchitti S, Di Pardo A, Sciarretta S, Rubattu S, **Maglione V**. Differential Expression of Sphingolipid Metabolizing Enzymes in Spontaneously Hypertensive Rats: A Possible Substrate for Susceptibility to Brain and Kidney Damage. *Int J Mol Sci*. 2021 Apr 6;22(7):3796.
13. Burtscher J, **Maglione V**, Di Pardo A, Millet GP, Schwarzer C, Zangrandi L. A Rationale for Hypoxic and Chemical Conditioning in Huntington's Disease. *Int J Mol Sci*. 2021 Jan 8;22(2):582
14. Pepe G, Calce E, Verdoliva V, Saviano M, **Maglione V**, Di Pardo A, De Luca S. Curcumin-Loaded Nanoparticles Based on Amphiphilic Hyaluronan-Conjugate Explored as Targeting Delivery System for Neurodegenerative Disorders. *Int J Mol Sci*. 2020 Nov 23;21(22):8846.
15. Burtscher J, Di Pardo A, **Maglione V***, Schwarzer C, Squitieri F. Mitochondrial Respiration Changes in R6/2 Huntington's Disease Model Mice during Aging in a Brain Region Specific Manner. *Int J Mol Sci*. 2020 Jul 30;21(15):5412. * **Co-corresponding Author**.
16. Di Pardo A, Ciaglia E, Cattaneo M, Maciag A, Montella F, Lopardo V, Ferrario A, Villa F, Madonna M, Amico E, Carrizzo A, Damato A, Pepe G, Marracino F, Auricchio A, Vecchione C, **Maglione V***, Puca AA. The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease. *Cell Death Dis*. 2020 Jul 18;11(7):546. * **Co-corresponding Author**.
17. Di Pardo A, Pepe G, Capocci L, Marracino F, Amico E, Del Vecchio L, Giova S, Jeong SK, Park BM, Park BD, **Maglione V**. Treatment with K6PC-5, a selective stimulator of SPHK1, ameliorates intestinal homeostasis in an animal model of Huntington's disease. *Neurobiol Dis*. 2020 Sep;143:105009.
18. Di Pardo A, Monyror J, Morales LC, Kadam V, Lingrell S, **Maglione V** Wozniak RW and Sipione S. Mutant huntingtin interacts with the sterol regulatory element-binding proteins and impairs their nuclear import. *Hum Mol Genet*. 2020 Feb 1;29(3):418-431.
19. Elifani F, Amico E, Pepe G, Capocci L, Castaldo S, Rosa P, Montano E, Pollice A, Madonna M, Filosa S, Calogero A, **Maglione V**, Crispi S and Di Pardo A. Curcumin dietary supplementation ameliorates disease phenotype in an animal model of Huntington's disease. *Hum Mol Genet*. 2019 Dec 1;28(23):4012-4021.
20. Bryan MR, O'Brien MT, Nordham KD, Daniel I.R. Rose DIR, Foshage AM, Joshi P, Nitin R, Uhouse MA, Di Pardo A, Zhang Z, **Maglione V**, Aschner M and Bowman AB. Acute manganese treatment restores defective autophagic cargo loading in Huntington's Disease cell lines. *Hum Mol Genet*. 2019 Nov 15;28(22):3825-3841.
21. Di Meo F, Filosa F, Madonna M, Giello G, Di Pardo A, **Maglione V**, Baldi A and Stefania Crispi S. Curcumin C3 complex®/Bioperine® has antineoplastic activity in mesothelioma: an in vitro and in vivo analysis. *J Exp Clin Cancer Res*. 2019; 38:360.
22. Vuono R, Kouli A, Legault EM, Chagnon, Allinson KS, La Spada A, ***REGISTRY** Investigators of the European Huntington's Disease Network, Biunno I, Barker RA and Janelle Drouin-Ouellet J. Association Between Toll-Like Receptor 4 (TLR4) and Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Genetic Variants and Clinical Progression of Huntington's Disease. *Mov Dis* *in press*. * Maglione is member of **REGISTRY**
23. Di Pardo A, Pepe G, Castaldo S, Marracino F, Capocci L, Amico E, Madonna M, Giova S, Jeong SK, Park BM, Park BD and **Maglione V**. Stimulation of Sphingosine Kinase 1 (SPHK1) is beneficial in

a Huntington's disease pre-clinical model. *Front Mol Neurosci.* eCollection 2019. 12, 100.

24. Di Pardo A, Castaldo S, Amico E, Pepe G, Marracino F, Capocci L, Giovannelli A, Madonna M, van Bergeijk J, Buttari F, van der Kam E, **Maglione V**. Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease. *Hum Mol Genet.* 2018 Jul 15;27(14):2490-2501.

25. Di Pardo A, **Maglione V**. The S1P Axis: New Exciting Route for Treating Huntington's Disease. *Trends Pharmacol Sci.* 2018 May;39(5):468-480.

26. Russo D, Della Ragione F, Rizzo R, Sugiyama E, Scalabri F, Hori K, Capasso S, Sticco L, Fioriniello S, De Gregorio R, Granata I, Guarracino MR, **Maglione V**, Johannes L, Bellenchi GC, Hoshino M, Setou M, D'Esposito M, Luini A, D'Angelo G. Glycosphingolipid metabolic reprogramming drives neural differentiation. *EMBO J.* 2018 Apr 3;37(7). pii: e97674.

27. Di Pardo A, **Maglione V**. Sphingolipid Metabolism: A New Therapeutic Opportunity for Brain Degenerative Disorders. *Front Neurosci.* 2018 Apr 17;12:249.

28. Di Meo F, Donato S, Di Pardo A, **Maglione V**, Filosa S, Crispi S. New Therapeutic Drugs from Bioactive Natural Molecules: The Role of Gut Microbiota Metabolism in Neurodegenerative Diseases. *Curr Drug Metab.* 2018;19(6):478-489.

29. Di Pardo A, Basit A, Armirotti A, Amico E, Castaldo S, Pepe G, Marracino F, Buttari F, Digilio AF, **Maglione V**. De novo synthesis of sphingolipids is defective in experimental models of Huntington's disease. *Front. Neurosci.* 2017; 11:698

30. Di Pardo A, Castaldo S, Capocci L, Amico E and **Maglione V**. Assessment of Blood-Brain Barrier Permeability by Intravenous Infusion of FITC-labelled Albumin in a Mouse Model of Neurodegenerative Disease. *JoVE J Vis Exp.* 2017 Nov 8;(129)

31. Di Pardo A and **Maglione V**. Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease. *NEURAL REGENERATION RESEARCH* September 2017, Volume 12, Issue 9

32. Di Pardo A, Amico E, Basit A, Armirotti A, Joshi P, Neely DM, Vuono R, Castaldo S, Digilio AF, Scalabri F, Pepe G, Elifani F, Madonna M, Jeong SK, Park BM, D'Esposito M, Bowman AB, Barker RA, **Maglione V**. Defective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease. *Sci Rep.* 2017 Jul 13;7(1):5280

33. Bichell TJ, Wegrzynowicz M, Grace Tipps K, Bradley EM, Uhouse MA, Bryan M, Horning K, Fisher N, Dudek K, Halbesma T, Umashanker P, Stubbs AD, Holt HK, Kwakye GF, Tidball AM, Colbran RJ, Aschner M, Diana Neely M, Di Pardo A, **Maglione V**, Osmand A, Bowman AB. Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model. *Biochim Biophys Acta.* 2017 Feb 14. pii: S0925-4439(17)30054-6.

34. Di Pardo A, Carrizzo A, Damato A, Castaldo S, Amico E, Capocci L, Ambrosio M, Pompeo F, De Sanctis C, Spinelli CC, Puca AA, Remondelli P, ***Maglione V** and ***Vecchione C**. Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) mice. *Sci Rep.* 2017 Feb 17;7:42797. *** Co-corresponding Authors**

35. Di Pardo A, Amico E, Scalabri F, Pepe G, Castaldo S, Elifani F, Capocci L, De Sanctis C, Comerci L, Pompeo F, D'Esposito M, Filosa S, Crispi S, **Maglione V**. Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease. *Sci Rep.* 2017 Jan 24;7:41316.

36. Di Pardo A, Amico E, **Maglione V**. Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models. *Front Neurosci*. 2016 Oct 6;10:457.
37. Luca G, Bellezza I, Arato I, Di Pardo A, Mancuso F, Calvitti M, Falabella G, Bartoli S, **Maglione V**, Amico E, Favellato M, Basta G, Bodo M, Minelli A, Calafiore R, Frati L, Squitieri F. Therapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease. *CNS Neurosci Ther*. 2016 Aug;22(8):686-90.
38. Squitieri F, Di Pardo A, Favellato M, Amico E, **Maglione V**, Frati L. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. *J Cell Mol Med*. 2015 Nov;19(1):2540-8.
39. Di Paola M, Phillips OR, Sanchez-Castaneda C, Di Pardo A, **Maglione V**, Caltagirone C, Sabatini U, Squitieri F. MRI measures of corpus callosum iron and myelin in early Huntington's disease. *Hum Brain Mapp*. 2014 Jul;35(7):3143-51.
40. Phillips O, Squitieri F, Sanchez-Castaneda C, Elifani F, Griguoli A, **Maglione V**, Caltagirone C, Sabatini U, Di Paola M. The Corticospinal Tract in Huntington's Disease. *Cereb Cortex*. 2015 Sep;25(9):2670-82.
41. Carrizzo A, Di Pardo A, **Maglione V**, Damato A, Amico E, Formisano L, Vecchione C, Squitieri F. Nitric oxide dysregulation in platelets from patients with advanced Huntington disease. *PLoS One*. 2014 Feb 25;9(2):e89745.
42. Di Pardo A, Alberti S, **Maglione V**, Amico E, Cortes EP, Elifani F, Battaglia G, Busceti CL, Nicoletti F, Vonsattel JP, Squitieri F. Changes of peripheral TGF- β 1 depend on monocytes-derived macrophages in Huntington disease. *Mol Brain*. 2013 Dec 13;6:55.
43. Di Pardo A, Amico E, Favellato M, Castrataro R, Fucile S, Squitieri F, **Maglione V**. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. *Hum Mol Genet*. 2014 May 1;23(9):2251-65.
44. Phillips O, Sanchez-Castaneda C, Elifani F, **Maglione V**, Di Pardo A, Caltagirone C, Squitieri F, Sabatini U, Di Paola M. Tractography of the corpus callosum in Huntington's disease. *PLoS One*. 2013 Sep 3;8(9):e73280. doi: 10.1371/journal.pone.0073280.
45. Metzger S, Walter C, Riess O, Roos RA, Nielsen JE, Craufurd D; ***REGISTRY** Investigators of the European Huntington's Disease Network., Nguyen HP. The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients. *PLoS One*. 2013 Jul 22;8(7):e68951. * Maglione is member of **REGISTRY**
46. Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; ***REGISTRY** investigators of the European Huntington's Disease Network.. Suicidal ideation in a European Huntington's disease population. *J Affect Disord*. 2013 Oct;151(1):248-58. * Maglione is member of **REGISTRY**
47. *Di Pardo A, *Maglione V, Alpaugh M, Horkey M, Atwal RS, Sassone J, Ciammola A, Steffan JS, Fouad K, Truant R, Sipione S. Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. *Proc Natl Acad Sci U S A*. 2012 Feb 28;109(9):3528-33. doi: 10.1073/pnas.114502109. * Equal contribution.
48. Saft C, Epplen JT, Wiczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D; **REGISTRY** Investigators of the European Huntington's Disease Network., Arning L. NMDA receptor gene variations as modifiers in Huntington disease: a replication

study. PLoS Curr. 201 Oct 4;3:RRN1247. * Maglione is member of **REGISTRY**

49. *Squitieri F, *Maglione V, Orobello S, Fornai F. Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells. J Neural Transm (Vienna). 2011 Nov;118(11):1599-607. * Equal contribution.

50. **Maglione V**, Marchi P, Di Pardo A, Lingrell S, Horkey M, Tidmarsh E, Sipione S. Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1. J Neurosci. 2010 Mar 17;30(1):4072-80.

51. Cannella M, **Maglione V**, Martino T, Ragona G, Frati L, Li GM, Squitieri F. DNA instability in replicating Huntington's disease lymphoblasts. BMC Med Genet. 2009 Feb 1 ;10:1 .

52. Gianfrancesco F, Esposito T, Penco S, **Maglione V**, Liquori CL, Patrosso MC, Zuffardi O, Ciccociola A, Marchuk DA, Squitieri F. ZPLD1 gene is disrupted in a patient with balanced translocation that exhibits cerebral cavernous malformations. Neuroscience. 2008 Aug 13;155(2):345-9.

53. Gianfrancesco F, Cannella M, Martino T, **Maglione V**, Esposito T, Innocenzi G, Vitale E, Liquori CL, Marchuk DA, Squitieri F. Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations. Am J Med Genet B Neuropsychiatr Genet. 2007 Jul 5;144B(5):691-5.

54. Mormone E, Matarrese P, Tinari A, Cannella M, **Maglione V**, Farrace MG, Piacentini M, Frati L, Malorni W, Squitieri F. Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease. J Neurochem. 2006 Aug;98(4):1090-9.

55. Liquori CL, Berg MJ, Squitieri F, Ottenbacher M, Sorlie M, Leedom TP, Cannella M, **Maglione V**, Ptacek L, Johnson EW, Marchuk DA. Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. Hum Mutat. 2006 Jan;27(1):118.

56. **Maglione V**, Cannella M, Gradini R, Cislighi G, Squitieri F. Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation. Mech Ageing Dev. 2006 Feb;127(2):213-6.

57. Squitieri F, Cannella M, Sgarbi G, **Maglione V**, Falleni A, Lenzi P, Baracca A, Cislighi G, Saft C, Ragona G, Russo MA, Thompson LM, Solaini G, Fornai F. Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation. Mech Ageing Dev. 2006 Feb;127(2):217-20.

58. **Maglione V**, Cannella M, Martino T, De Blasi A, Frati L, Squitieri F. The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea. Neurosci Lett. 2006 Jan 23;393(1):27-30.

59. **Maglione V**, Giallonardo P, Cannella M, Martino T, Frati L, Squitieri F. Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Nov 5;139B(1):101-5.

60. Cannella M, **Maglione V**, Martino T, Simonelli M, Ragona G, Squitieri F. New Huntington disease mutation arising from a paternal CAG34 allele showing somatic length variation in serially passaged lymphoblasts. Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 5;133B(1):127-30.

61. Cannella M, Gellera C, **Maglione V**, Giallonardo P, Cislighi G, Muglia M, Quattrone A, Pierelli F, Di

Donato S, Squitieri F. The gender effect in juvenile Huntington disease patients of Italian origin. *Am J Med Genet B Neuropsychiatr Genet*. 2004 Feb 15;125B(1):92-8. PubMed PMID: 14755452.

62. Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T, Verlaan D, Balogun F, Hughes L, Leedom TP, Plummer NW, Cannella M, **Maglione V**, Squitieri F, Johnson EW, Rouleau GA, Ptacek L, Marchuk DA. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. *Am J Hum Genet*. 2003 Dec;73(6):1459-64.

63. Squitieri F, Cannella M, Gaudio L, Martino T, **Maglione V**, Giallonardo P, Simonelli M, Simonelli G, Mangeruga D, Ciarmiello A, Pierelli F. Italian Huntington disease patients--data and tissue bank. *Neurol Sci*. 2003 Oct;24(3):215-6.

64. Squitieri F, Pustorino G, Cannella M, Toscano A, **Maglione V**, Morgante L, Tortorella G. Highly disabling cerebellar presentation in Huntington disease. *Eur J Neurol*. 2003 Jul;10(4):443-4.

65. Squitieri F, Gellera C, Cannella M, Mariotti C, Cislighi G, Rubinsztein DC, Almqvist EW, Turner D, Bachoud-Lévi AC, Simpson SA, Delatycki M, **Maglione V**, Hayden MR, Donato SD. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. *Brain*. 2003 Apr;126(Pt 4):946-55.

66. Squitieri F, Cannella M, Giallonardo P, **Maglione V**, Mariotti C, Hayden MR. Onset and pre-onset studies to define the Huntington's disease natural history. *Brain Res Bull*. 2001 Oct-Nov 1;56(3-4):233-8.

67. Squitieri F, **Maglione V**, Buzzi MG, Nargi E, Novelletto A, Cannella M, Simonelli M, Colonnese C, Simonelli P, Innocenzi G, Gagliardi FM, Caruso R, Ragona G, Cantore GP. Cavernous angiomas of the nervous system in Italy: clinical and genetic study. *Neurol Sci*. 2000 Jun;21(3):129-34.

Vittorio Maglione

Elenco pubblicazioni e titoli (dottorato, fellowship ed attività didattica)

Pubblicazioni

(Le pubblicazioni sono riportate in PDF originale, scaricato da ogni singola rivista scientifica)

1. Ferlazzo GM, Gambetta AM, Amato S, Cannizzaro N, Angiolillo S, Arboit M, Diamante L, Carbognin E, Romani P, La Torre F, Galimberti E, Pflug F, Luoni M, Giannelli S, Pepe G, Capocci L, Di Pardo A, Vanzani P, Zennaro L, Broccoli V, Leeb M, Moro E, **Maglione V**, Martello G. Genome-wide screening in pluripotent cells identifies Mtf1 as a suppressor of mutant huntingtin toxicity. *Nat Commun.* **2023** Jul 5;14(1):3962. doi: 10.1038/s41467-023-39552-9.
2. Pepe G, Capocci L, Marracino F, Realini N, Lenzi P, Martinello K, Bovier TF, Bichell TJ, Scarselli P, Di Cicco C, Bowman AB, Digilio FA, Fucile S, Fornai F, Armirotti A, Parlato R, Di Pardo A, **Maglione V**. Treatment with THI, an inhibitor of sphingosine-1-phosphate lyase, modulates glycosphingolipid metabolism and results therapeutically effective in experimental models of Huntington's disease. *Mol Ther.* **2023** Sep 16:S1525-0016(22)00558-5.
3. Palomba NP, Fortunato G, Pepe G, Modugno N, Pietracupa S, Damiano I, Mascio G, Carrillo F, Di Giovannantonio LG, Ianiro L, Martinello K, Volpato V, Desiato V, Acri R, Storto M, Nicoletti F, Webber C, Simeone A, Fucile S, **Maglione V**, Esposito T. Common and Rare Variants in TMEM175 Gene Concur to the Pathogenesis of Parkinson's Disease in Italian Patients. *Mol Neurobiol.* **2023** Apr;60(4):2150-2173. doi: 10.1007/s12035-022-03203-9
4. Pepe G, Cotugno M, Marracino F, Giova S, Capocci L, Forte M, Stanzione R, Bianchi F, Marchitti S, Di Pardo A, Sciarretta S, Rubattu S, **Maglione V**. Differential Expression of Sphingolipid Metabolizing Enzymes in Spontaneously Hypertensive Rats: A Possible Substrate for Susceptibility to Brain and Kidney Damage. *Int J Mol Sci.* **2021** Apr 6;22(7):3796.
5. Di Pardo A, Ciaglia E, Cattaneo M, Maciag A, Montella F, Lopardo V, Ferrario A, Villa F, Madonna M, Amico E, Carrizzo A, Damato A, Pepe G, Marracino F, Auricchio A, Vecchione C, **Maglione V***, Puca AA. The longevity-associated variant of BPIFB4 improves a CXCR4-mediated striatum-microglia crosstalk preventing disease progression in a mouse model of Huntington's disease. *Cell Death Dis.* **2020** Jul 18;11(7):546. * **Co-corresponding Author**.
6. Cannella M, **Maglione V**, Martino T, Ragona G, Frati L, Li GM, Squitieri F. DNA instability in replicating Huntington's disease lymphoblasts. *BMC Med Genet.* **2009** Feb 11;10:11.
7. Gianfrancesco F, Esposito T, Penco S, **Maglione V**, Liquori CL, Patrosso MC, Zuffardi O, Ciccodicola A, Marchuk DA, Squitieri F. ZPLD1 gene is disrupted in a patient with balanced translocation that exhibits cerebral cavernous malformations. *Neuroscience.* **2008** Aug 13;155(2):345-9.

8. Gianfrancesco F, Cannella M, Martino T, **Maglione V**, Esposito T, Innocenzi G, Vitale E, Liquori CL, Marchuk DA, Squitieri F. Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations. **Am J Med Genet B Neuropsychiatr Genet.** 2007 Jul 5;144B(5):691-5.
9. Liquori CL, Berg MJ, Squitieri F, Ottenbacher M, Sorlie M, Leedom TP, Cannella M, **Maglione V**, Ptacek L, Johnson EW, Marchuk DA. Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. **Hum Mutat.** 2006 Jan;27(1):118.
10. Cannella M, **Maglione V**, Martino T, Simonelli M, Ragona G, Squitieri F. New Huntington disease mutation arising from a paternal CAG34 allele showing somatic length variation in serially passaged lymphoblasts. **Am J Med Genet B Neuropsychiatr Genet.** 2005 Feb 5;133B(1):127-30.
11. Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T, Verlaan D, Balogun F, Hughes L, Leedom TP, Plummer NW, Cannella M, **Maglione V**, Squitieri F, Johnson EW, Rouleau GA, Ptacek L, Marchuk DA. Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. **Am J Hum Genet.** 2003 Dec;73(6):1459-64.
12. Squitieri F, **Maglione V**, Buzzi MG, Nargi E, Novelletto A, Cannella M, Simonelli M, Colonnese C, Simonelli P, Innocenzi G, Gagliardi FM, Caruso R, Ragona G, Cantore GP. Cavernous angiomas of the nervous system in Italy: clinical and genetic study. **Neurol Sci.** 2000 Jun;21(3):129-34.

Titoli (dottorato, fellowship ed attività didattica)

1. Certificato di Dottorato in Neurobiologia, Università di Catania (copia conforme all'originale, si veda dichiarazione)
2. Certificato Conseguimento Borsa di Studio "Marie Curie" (titolo in originale)
3. Certificato AHFMR Fellowship, Università dell'Alberta, Edmonton, Canada (copia conforme all'originale, si veda dichiarazione)
4. Certificato degli insegnamenti di Biologia e Biochimica, Corso di Laurea in Logopedia, Università di Roma Tor Vergata" (copia conforme all'originale, si veda dichiarazione)

